Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
NCT01273896
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
STA-9090
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
[object Object]